title: Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group.
abstract: BACKGROUND
  Data concerning appropriate treatment in panic disorder following an initial response to acute therapy are limited.
  
  
  OBJECTIVE
  To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder.
  
  
  METHODS
  Patients who responded to acute fluoxetine treatment were randomised to 24 weeks of continued fluoxetine or placebo.
  
  
  RESULTS
  Fluoxetine responders randomised to continue on their acute-phase fluoxetine dose experienced statistically significant improvement in panic attack frequency and phobia rating scale score over 24 weeks of therapy, while those switched to placebo experienced statistically significant worsening in Hamilton Anxiety (HAM-A), Hamilton Depression (HAM-D) and SCL-90-R rating scores.
  
  
  CONCLUSIONS
  Fluoxetine was associated with improved clinical outcomes compared with placebo during continuation therapy.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianpolis, IN 46285, USA.
authors.forename: D
authors.initials: D
authors.lastname: Michelson
authors.forename: M
authors.initials: M
authors.lastname: Pollack
authors.forename: R B
authors.initials: RB
authors.lastname: Lydiard
authors.forename: R
authors.initials: R
authors.lastname: Tamura
authors.forename: R
authors.initials: R
authors.lastname: Tepner
authors.forename: G
authors.initials: G
authors.lastname: Tollefson
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy*; D010919:Placebos; D012008:Recurrence; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010919:Placebos; D005473:Fluoxetine